Sharechat Logo

TrustPower in tax battle over treatment of resource consents

Wednesday 27th June 2012

Text too small?

TrustPower may have to record a tax expense of as much as $3.3 million in its income statements if a dispute with the Inland Revenue Department (IRD) goes against it, according to shareholder Infratil.

The contingent liabilities section of the Infratil annual report discloses that IRD is currently disputing the tax treatment of feasibility expenditure booked by TrustPower in 2006, 2007 and 2008.

TrustPower disagrees with IRD and is defending its position.

Infratil says that if TrustPower loses it may have to pay taxes of $5.9 million and interest of $2.8 million for the 2006, 2007 and 2008 financial years.

If TrustPower has to revise its policy for capitalising the cost of resource consents for tax it will also face a tax payment of $4.1 million and interest expense of $0.8 million in respect of the 2009, 2010, 2011 and 2012 years.

The tax dispute would primarily result in balance sheet adjustments, Infratil said.

The impact on the income statement was difficult to estimate but it was "unlikely to exceed $3.3 million" for all years up to 2012, because the initial expenses are eligible for depreciation charges, which would partially offset the additional tax charges.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report